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1  | BACKGROUND
Metastatic breast cancer (MBC) remains incurable, and few cyto-
toxic agents prolong overall survival (OS). Several cytotoxic ther-
apies are approved for treating patients with MBC, and current 
clinical guidelines generally recommend sequential monotherapies, 
but not a preferred sequence of administration.1
Eribulin, a synthetic analogue of halichondrin B, inhibits micro-
tubule growth, blocks cell-cycle progression, and induces apoptosis 
of tumor cells.2 In preclinical studies, eribulin induced vascular re-
modeling and increased tumor perfusion3; similarly, noncytotoxic ef-
fects have been demonstrated clinically.4 Eribulin mesylate (eribulin) 
is approved in the United States for the treatment of patients with 
MBC after ≥2 prior chemotherapies for metastatic disease; addition-
ally, it is approved in the European Union for locally advanced/MBC 
patients with ≥1 prior chemotherapies for advanced disease. Prior 
treatments should include a taxane and an anthracycline.
Two randomized, open-label, phase 3 trials (Study 305/EMBRACE 
and Study 301 [ClinicalTrials.gov: NCT00388726 and NCT00337103, 
respectively]) assessed the efficacy and safety of eribulin in pre-
treated patients with locally recurrent/MBC.5,6 In a previous pooled 
analysis of these 2 studies,7 median OS was 15.2 months (eribulin) 
versus 12.8 months (control arm: hazard ratio [HR], 0.85; 95% confi-
dence interval [CI] 0.77-0.95; P = .003); OS favored eribulin in all an-
alyzed subgroups including human epidermal growth factor receptor 
2 (HER2)-negative disease (HR, 0.82; P = .002), and triple-negative 
disease (HR, 0.74; P = .006). These findings were supported by another 
pooled analysis in patients with ≥1 prior chemotherapy regimens.8 
Here, we report an exploratory, post hoc, pooled subgroup analysis 
of the influence of the number of prior chemotherapy regimens on OS 
using data from EMBRACE and Study 301.
2  | METHODS
Both trials enrolled women aged ≥18 years, with previously treated 
locally recurrent/MBC.5,6 OS was compared between eribulin and 
treatment of physician's choice [TPC] (EMBRACE) or capecitabine 
 
Received: 15 October 2019  |  Accepted: 18 October 2019
DOI: 10.1111/tbj.13686  
S H O R T  C O M M U N I C A T I O N
Impact of the number of prior chemotherapy regimens on 
outcomes for patients with metastatic breast cancer treated 
with eribulin: A post hoc pooled analysis
Javier Cortes MD, PhD1,2 |   Chris Twelves MD3
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2019 The Authors. The Breast Journal published by Wiley Periodicals, Inc.
1IOB Institute of Oncology, Quironsalud 
Group, Madrid & Barcelona, Spain
2Vall d´Hebron Institute of Oncology, 
Barcelona, Spain
3Leeds Institute of Medical Research at 
St James's, University of Leeds and Leeds 
Teaching Hospitals Trust, Leeds, UK
Correspondence
Javier Cortes, IOB Institute of Oncology, 
Quironsalud Group, Madrid & Barcelona, 
Ruber International Hospital, Calle de La 
Mason 38, 28034 Madrid, Spain.
Email: jacortes@vhio.net
Funding information
Eisai Inc. NJ, USA
Abstract
In a pivotal phase 3 study (Study 305), eribulin mesylate improved overall survival 
(OS) in patients with previously treated metastatic breast cancer (MBC) compared 
with treatment of physician's choice (TPC). This post hoc, pooled subgroup analysis of 
two phase 3 studies (Study 305 and Study 301) reports the influence of the number 
of prior chemotherapy regimens (0-6) on OS in patients with locally advanced/MBC 
randomized to eribulin versus TPC/capecitabine. Patients with ≤ 3 prior chemothera-
pies for locally advanced/MBC had longer median OS with eribulin (15.3 months) 
versus control (13.2 months; hazard ratio, 0.858; P = .01).
K E Y W O R D S
advanced breast cancer, efficacy analysis, eribulin, overall survival, safety
2  |     CORTES and TWELVES
(Study 301) in the intent-to-treat (ITT) populations.5,6 HRs for 
EMBRACE only were based on a Cox regression model including 
HER2/neu status, geographical region, and prior capecitabine treat-
ment as stratification variables.5 HRs for pooled data were esti-
mated based on the Cox model with stratification factors (HER2 
status, region, prior capecitabine use, and study). Median OS was 
adjusted by study (defined in Twelves et al, 20147) and P-values 
were estimated by stratified log-rank test. An exploratory compara-
tive analysis of OS grouped by ≤3 versus >3 prior treatments, and by 
individual number of prior lines of treatment (ie, 0, 1, 2, 3, 4, 5, and 
6), for locally advanced/MBC was completed using data pooled from 
both studies except as noted (ie, data on ≥5 prior lines of therapy 
are from EMBRACE only). A pooled analysis of safety data was not 
possible because the studies used different versions of the Medical 
Dictionary for Regulatory Activities (version 10.0 for EMBRACE, 
version 14.1 for Study 301).
3  | RESULTS
3.1 | Patients
In EMBRACE, patients were randomized 2:1 to receive eribulin 
(1.4 mg/m2 [equivalent to 1.23 mg/m2 when expressed as a free 
base] intravenously on days 1 and 8 every 21 days; n = 508) or TPC 
(n = 254).5 In Study 301, 554 patients were randomized to receive 
eribulin and 548 to receive capecitabine.6 Patient characteristics have 
been previously reported.5,6 Almost all (99%) patients had received 
prior anthracycline and taxane therapy.5,6 In EMBRACE, the median 
number of prior chemotherapy regimens for locally advanced/MBC 
was 3 (with approximately one-quarter having >3 and three-quarters 
having ≤3). In Study 301, only 1 patient (a protocol deviation) received 
>3 prior chemotherapy regimens for locally advanced/MBC.
3.2 | Post hoc efficacy analysis
This subgroup analysis demonstrated a nominally significant dif-
ference in median OS with eribulin treatment (ITT group, n = 945) 
versus control (n = 727) in patients who received ≤ 3 prior chemo-
therapy regimens for locally advanced/MBC (15.3 vs 13.2 months, 
respectively; HR, 0.858; P = .01; Table 1, Figure 1). In EMBRACE, 
patients with >3 prior regimens for locally advanced/MBC had a me-
dian OS in the eribulin (n = 117) versus TPC (n = 73) ITT groups of 
11.7 versus 10.0 months, respectively; this improvement was again 
nominally significantly different in patients with ≤3 prior chemo-
therapy regimens for locally advanced/MBC (eribulin, n = 391; TPC, 
n = 180; 13.3 vs 10.7 months, respectively; P = .039; Table 1).
Additional exploratory pooled post hoc analysis for patients re-
ceiving 0-6 prior lines of therapy showed a trend for higher OS in pa-
tients treated with eribulin compared with control (Table 2), and this 
trend was emphasized in those patients with 0-3 prior lines of ther-
apy compared with those who had been more heavily pretreated. 
TA B L E  1   Overall survival for locally advanced/MBC patients 
with ≤3 or >3 prior chemotherapy regimens
Parameter
Patients randomized 
to receive Median 
survival 
differenceEribulin Control
≤3 Prior chemotherapy regimens (EMBRACE)
n 391 180  
Median overall survival 13.3 moa
404 d
10.7 moa
326 d
2.6 moa
78 d
95% CI, days 365.0-454.0 282.0-380.0
P-valueb .039
Hazard ratioc  
(eribulin vs TPC)
0.774
95% CI 0.606-0.988
≤3 Prior chemotherapy regimens (pooled data from Study 301 and 
EMBRACE)
n 945 727
Median overall survival 15.3 mo
466 d
13.2 mo
402 d
2.1 mo
64 d
95% CI, days 438.3-484.0 365.3-441.3
P-valueb .010
Hazard ratiod  
(eribulin vs controle)
0.858
95% CI 0.764-0.964
>3 Prior chemotherapy regimens (EMBRACE)
n 117 73
Median overall survival 11.7 moa 10.0 moa
355 d 304 d
95% CI, days 281.0-420.0 191.0-547.0
P-valueb .607
Hazard ratioc  
(eribulin vs TPC)
0.899
95% CI 0.600-1.348
Note: CI, confidence interval; HER2, human epidermal growth factor 
receptor 2; ITT, intent-to-treat; TPC, treatment of physician's choice.
aA conversion factor of 30.4375 was used to convert number of days 
into months. 
bBased on stratified log-rank test, for Study 301, strata included HER2/
neu status (clinical database) and geographical region; for analyses 
of EMBRACE, strata included HER2/neu status (clinical database), 
geographical region, and prior capecitabine treatment; for pooled 
analyses, strata included study, geographical region, prior capecitabine 
use, and HER2/neu status. 
cHazard ratios and the corresponding 95% CI were generated based on 
a Cox regression model with stratification factors of: HER2/neu status, 
prior capecitabine treatment (for EMBRACE), and geographical region. 
dHazard ratios and the corresponding 95% CI were generated based 
on the Cox regression model, with stratification factors of: study, 
geographical region (North America/Western Europe/Australia, Latin 
America/South Africa, Eastern Europe, Asia), prior capecitabine use, 
and HER2/neu status. 
eThe control treatments were TPC for EMBRACE and capecitabine for 
Study 301. 
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However, caution is warranted due to the low number of patients, 
especially in the latter subgroups.
3.3 | Safety
The number of prior chemotherapies appeared not to affect the 
safety of eribulin in EMBRACE. Although neutropenia and asthenia/
fatigue rates were higher with eribulin treatment compared with 
control, the incidences of both were similar regardless of whether 
patients had ≤3 or >3 prior regimens (neutropenia, 51.7% for both 
subgroups; asthenia/fatigue, 53.2% vs 55.1% for ≤3 vs >3, respec-
tively). For patients in the TPC group, the incidences of neutropenia 
(30.9% vs 25%) and asthenia/fatigue (40.4% vs 36.8%) were nu-
merically higher in patients having ≤3 prior regimens compared with 
those having >3 prior regimens.
4  | DISCUSSION
This exploratory subgroup analysis of EMBRACE5 and Study 3016 
shows that the OS benefit conferred by eribulin over TPC/capecitabine 
is predominantly seen in patients who had fewer prior regimens (≤3) 
for locally advanced/MBC with a median OS benefit of 2.1 months. 
This difference in OS was also observed in EMBRACE alone (≤3 prior 
regimens, 2.6 months; >3 prior regimens, 1.7 months); the number of 
prior regimens appeared not to affect the safety of eribulin.
The pooled subgroup analysis by number of prior regimens showed 
that eribulin conferred an OS benefit of 1.2, 1.6, and 1.5 months for 
patients treated with 0, 1, or 2 prior regimens for locally advanced/
MBC, respectively, with a 5.0-month OS benefit observed for patients 
with 3 prior regimens (HR, 0.608; P = .0098). Patient numbers were, 
however, not large enough to draw conclusions regarding the relative 
efficacy of eribulin in patients who had received 0, 1, 2, or 3 prior che-
motherapy regimens. Benefit from eribulin appeared reduced in more 
heavily pretreated patients, but patient numbers were small, especially 
for those with 6 prior regimens (9 patients).
The greater benefits of eribulin when used in earlier-line set-
tings are supported by other studies.9,10 In a post hoc subgroup 
analysis of patients (n = 392) in Study 301, treated in the second-line 
setting,10 median OS was longer in those with HER2-negative 
MBC receiving eribulin versus capecitabine (16.1 vs 13.5 months, 
respectively; HR, 0.77; P = .026). A large-scale clinical study in 
patients with advanced/MBC, randomized to receive eribulin or 
vinorelbine,9 also achieved its primary end point of prolonged pro-
gression-free survival (HR, 0.80; P = .036). Again, the benefit in 
progression-free survival from eribulin was seen in patients who 
had received fewer prior regimens for metastatic disease (≤2; HR, 
0.69; 95% CI 0.53-0.91) but not in those who had been more heav-
ily pretreated (>2; HR, 0.91; 95% CI 0.66-1.25).9
F I G U R E  1   Overall Survival Curves for Patients Pooled From Study 3016 and EMBRACE5 (ITT Population). Populations comprised those 
who received ≤3 prior chemotherapy regimens for advanced or metastatic breast cancer. Note, CI, confidence interval; “control,” control 
treatments were either treatment of physician's choice or capecitabine; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; 
ITT, intent-to-treat population. Overall survival and medians were calculated per study adjustment following the same method outlined 
previously.7 P-value was based on stratified log-rank test. The HR (eribulin/control) and the corresponding 95% CIs were generated based on 
the Cox regression model, with stratification factors of study, region (North America/Western Europe/Australia, Latin America/South Africa, 
Eastern Europe, and Asia), prior capecitabine use, and HER2/neu status
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Despite the post hoc nature and small sample size (especially for 
patients with >3 prior regimens for locally advanced/MBC), this study 
suggests there may be potential benefit in using eribulin to treat pa-
tients with locally advanced/MBC sooner rather than later. As there is 
considerable attrition in patients receiving successive lines of therapy, 
it is appropriate that treatments demonstrating the greatest benefit 
are used earlier for patients with locally advanced/MBC.
5  | CONCLUSIONS
Patients who have received 3 or fewer regimens for locally advanced/
MBC showed an improvement in OS if treated with eribulin rather 
than with TPC/capecitabine. Clinicians should consider the use of 
eribulin as indicated and available for the treatment of such patients.
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